RTX-117

N/A

Report date: 2026/01/19 10:38:04
NME

Base Information

Drug NameRTX-117
Drug Alias NameRTX-117
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEukaryotic translation initiation factor 2B activators
TargetsEukaryotic translation initiation factor 2B
Therapy Area/IndicationsNerve DegenerationCharcot-Marie-Tooth DiseaseBrain Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesReviR Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesXili Technology (Shenzhen) Co LtdReviR Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsNerve DegenerationCharcot-Marie-Tooth DiseaseBrain Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A